Fas ligand (FasL, CD95L), a member of the TNF family of proteins, is best known for its ability to deliver apoptotic death signals through Fas (CD95). Work from our laboratory has demonstrated that FasL can also deliver costimulatory signals in the reverse direction. FasL-mediated costimulation enhances the in vivo and in vitro burst size of both polyclonal and monoclonal antigen-activated CD8+ T cells. Furthermore, FasL influences thymocyte maturation of T cells expressing receptors of moderate affinity for their selecting ligands. The mechanism of FasL-mediated costimulation and the nature of the transduced signal remain unexplored. One overall goal of the proposed experiments is to delineate how crosslinking FasL delivers a costimulatory signal, and how this signal is interpreted at the level of T cell function and the ability to mount an effective immune response to an invading pathogen. Fas interacts with FasL and transduces a death signal. Natural mutations in Fas that prevent initiation of this death cascade lead to lymphoproliferative disorders in both mice and humans. While it has been assumed that defective activation-induced cell death is one basis for this lymphoproliferation, it is not yet known whether expression of death-incompetent Fas molecules by T cells is necessary and sufficient to initiate lymphadenopathy and the accumulation of unusual Thy-1+B220+CD4-CD8- T cells. It is also unclear what Fas+ cell interacts with FasL+ T cells to deliver a costimulatory signal. A second overall goal of the proposed experiments is to investigate the role of Fas on activated T cells in lymphocyte homeostasis and to identify the Fas-expressing cell that initiates FasL-mediated costimulation. The following Specific Aims have been devised to address these goals.
Specific Aim 1 : To explore the mechanism of costimulation by reverse signaling through FasL.
Specific Aim 2 : To determine the in vivo consequences on immune responses of deficient costimulation through FasL.
Specific Aim 3 : To use mice bearing a floxed allele of Fas to determine in what cell population(s) loss of Fas expression drives the Ipr phenotype and to identify what cell costimulates T cell responses through FasL in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI044130-10
Application #
7575188
Study Section
Cellular and Molecular Immunology - B (CMI)
Program Officer
Lapham, Cheryl K
Project Start
1999-07-15
Project End
2011-02-28
Budget Start
2009-03-01
Budget End
2011-02-28
Support Year
10
Fiscal Year
2009
Total Cost
$286,694
Indirect Cost
Name
University of Washington
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Stranges, Peter B; Watson, Jessica; Cooper, Cristie J et al. (2007) Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. Immunity 26:629-41
Sun, Mingyi; Lee, Shinhee; Karray, Saoussen et al. (2007) Cutting edge: two distinct motifs within the Fas ligand tail regulate Fas ligand-mediated costimulation. J Immunol 179:5639-43
Sun, Mingyi; Ames, Kristina T; Suzuki, Ivy et al. (2006) The cytoplasmic domain of Fas ligand costimulates TCR signals. J Immunol 177:1481-91
Boursalian, Tamar E; Golob, Jonathan; Soper, David M et al. (2004) Continued maturation of thymic emigrants in the periphery. Nat Immunol 5:418-25
Ali, Mohamed; Weinreich, Michael; Balcaitis, Stephanie et al. (2003) Differential regulation of peripheral CD4+ T cell tolerance induced by deletion and TCR revision. J Immunol 171:6290-6
Boursalian, Tamar E; Fink, Pamela J (2003) Mutation in fas ligand impairs maturation of thymocytes bearing moderate affinity T cell receptors. J Exp Med 198:349-60
Suzuki, I; Fink, P J (2000) The dual functions of fas ligand in the regulation of peripheral CD8+ and CD4+ T cells. Proc Natl Acad Sci U S A 97:1707-12
Suzuki, I; Martin, S; Boursalian, T E et al. (2000) Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J Immunol 165:5537-43